SAGE Therapeutics, Inc. (US) ( (SAGE) ) has released its Q1 earnings. Here is a breakdown of the information SAGE Therapeutics, Inc. (US) presented to its investors.
Sage Therapeutics, Inc., a biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing innovative treatments for brain health, including the first FDA-approved oral treatment for postpartum depression (PPD).
In its first quarter of 2025, Sage Therapeutics reported a significant increase in revenue and shipments for its flagship product, ZURZUVAE, which is used to treat postpartum depression. The company achieved $13.8 million in collaboration revenue, marking a 21% increase from the previous quarter, and saw a 22% rise in shipments to women with PPD.
Key financial highlights include a cash position of $424 million, which is expected to support operations until mid-2027. The company also reported a net loss of $62.2 million, an improvement from the $108.5 million loss in the same period of 2024. Sage’s strategic focus remains on expanding the market for ZURZUVAE and advancing its pipeline, including the development of SAGE-319 for neurodevelopmental disorders.
Sage Therapeutics continues to explore strategic alternatives to maximize shareholder value, with ongoing evaluations and no set timetable for completion. The company remains committed to establishing ZURZUVAE as the standard of care for PPD and anticipates a decrease in overall operating expenses in 2025 compared to 2024.
Looking ahead, Sage Therapeutics aims to drive significant top-line revenue growth through increased commercialization efforts for ZURZUVAE and continued development of its pipeline, while maintaining a strong cash position to support its strategic initiatives.